MindImmune Therapeutics agrees to acquire two programs from H. Lundbeck

MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
MINDIMMUNE THERAPEUTICS has entered into an agreement with Lundbeck tow acquire two programs related to neuropathic pain and Huntington's disease. / COURTESY MINDIMMUNE THERAPEUTICS
SOUTH KINGSTOWN –MindImmune Therapeutics Inc. has entered into agreements with H. Lundbeck A/S to acquire programs and will develop candidates from these programs as novel therapeutics to treat neuropathic pain and Huntington’s disease, the company announced Wednesday. The programs target two neuroinflammation targets: P2X7 receptors and KMO, an enzyme in the neuroimmune kynurenine-signaling pathway, according…
To read the full story, Subscribe or
Subscribe to PBN
- Advertisement -